Literature DB >> 21549593

Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.

Nikunj M Shukla1, Tyler C Lewis, Timothy P Day, Cole A Mutz, Rehman Ukani, Chase D Hamilton, Rajalakshmi Balakrishna, Sunil A David.   

Abstract

Toll-like receptor (TLR)-7 agonists show prominent Th1-biased immunostimulatory activities. A TLR7-active N(1)-(4-aminomethyl)benzyl substituted imidazoquinoline 1 served as a convenient precursor for the syntheses of isothiocyanate and maleimide derivatives for covalent attachment to free amine and thiol groups of peptides and proteins. 1 was also amenable to direct reductive amination with maltoheptaose without significant loss of activity. Covalent conjugation of the isothiocyanate derivative 2 to α-lactalbumin could be achieved under mild, non-denaturing conditions, in a controlled manner and with full preservation of antigenicity. The self-adjuvanting α-lactalbumin construct induced robust, high-affinity immunoglobulin titers in murine models. The premise of covalently decorating protein antigens with adjuvants offers the possibility of drastically reducing systemic exposure of the adjuvant, and yet eliciting strong, Th1-biased immune responses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549593      PMCID: PMC3098923          DOI: 10.1016/j.bmcl.2011.04.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  43 in total

1.  IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen.

Authors:  M Eberl; E Beck; P S Coulson; H Okamura; R A Wilson; A P Mountford
Journal:  Vaccine       Date:  2000-04-03       Impact factor: 3.641

Review 2.  Toll-like receptors: critical proteins linking innate and acquired immunity.

Authors:  S Akira; K Takeda; T Kaisho
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

Review 3.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

4.  Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.

Authors:  Brendan L Wilkinson; Stephanie Day; Lara R Malins; Vasso Apostolopoulos; Richard J Payne
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-07       Impact factor: 15.336

5.  Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.

Authors:  Nikunj M Shukla; Subbalakshmi S Malladi; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

6.  Lipidation of intact proteins produces highly immunogenic vaccine candidates.

Authors:  Weiguang Zeng; Emily M Eriksson; Andrew Lew; David C Jackson
Journal:  Mol Immunol       Date:  2010-11-05       Impact factor: 4.407

7.  Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines.

Authors:  F Falugi; R Petracca; M Mariani; E Luzzi; S Mancianti; V Carinci; M L Melli; O Finco; A Wack; A Di Tommaso; M T De Magistris; P Costantino; G Del Giudice; S Abrignani; R Rappuoli; G Grandi
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

8.  Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.

Authors:  Wenyan Wu; Rongti Li; Subbalakshmi S Malladi; Hemamali J Warshakoon; Matthew R Kimbrell; Michael W Amolins; Rehman Ukani; Apurba Datta; Sunil A David
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

9.  An autoimmune-mediated strategy for prophylactic breast cancer vaccination.

Authors:  Ritika Jaini; Pavani Kesaraju; Justin M Johnson; Cengiz Z Altuntas; Daniel Jane-Wit; Vincent K Tuohy
Journal:  Nat Med       Date:  2010-05-30       Impact factor: 53.440

10.  Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Authors:  Deepa Rajagopal; Carine Paturel; Yannis Morel; Satoshi Uematsu; Shizuo Akira; Sandra S Diebold
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

View more
  25 in total

1.  Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Authors:  Geetanjali Agnihotri; Breanna M Crall; Tyler C Lewis; Timothy P Day; Rajalakshmi Balakrishna; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

2.  Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting Immunopotentiators.

Authors:  Dong Gao; Yu Liu; Yuwen Diao; Ningning Gao; Zhulin Wang; Wenqi Jiang; Guangyi Jin
Journal:  ACS Med Chem Lett       Date:  2015-01-30       Impact factor: 4.345

3.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

4.  Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

Authors:  Rehman Ukani; Tyler C Lewis; Timothy P Day; Wenyan Wu; Subbalakshmi S Malladi; Hemamali J Warshakoon; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-11-09       Impact factor: 2.823

5.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

6.  Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authors:  Jooeun Bae; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

7.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

8.  TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.

Authors:  Victoria Jeisy-Scott; Jin Hyang Kim; William G Davis; Weiping Cao; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

9.  Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

Authors:  Deepak B Salunke; Euna Yoo; Nikunj M Shukla; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Katelyn J Serafin; Victor W Day; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2012-09-07       Impact factor: 7.446

10.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.